Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country
Status PubMed-not-MEDLINE Language English Country Switzerland Media electronic
Document type Journal Article
Grant support
856620
European Commission
PubMed
35454845
PubMed Central
PMC9030935
DOI
10.3390/cancers14081938
PII: cancers14081938
Knihovny.cz E-resources
- Keywords
- alcohol, discordant familial risks, gallbladder cancer, hepatocellular carcinoma, risk factors, spouse correlation,
- Publication type
- Journal Article MeSH
We used the Swedish Cancer Registry data to address familial risks for concordant (same) and discordant (different) hepatobiliary cancers, including their associations with any other cancers and with known risk factors. Risks were also assessed between spouses. The analysis covered Swedish families and their cancers between years 1958 and 2018. Adjusted familial risks were expressed as standardized incidence ratios (SIRs). Familial SIRs for concordant hepatocellular carcinoma (HCC) were 2.60, and for gallbladder cancer they were at the same level (2.76). Familial risk was also found for intrahepatic bile duct cancer and for female extrahepatic bile duct cancer. HCC was associated with lung and cervical cancers; extrahepatic bile duct and ampullary cancers were associated with colon and pancreatic cancers, suggesting Lynch syndrome. Among spouses, hepatobiliary cancer was associated with HCC, stomach, pancreatic, cervical and upper aerodigestive tract cancers. Among risk factors, family members diagnosed with alcohol-related disease showed association with HCC. The observed familial risks for hepatobiliary cancers were relatively high, and considering the poor prognosis of these cancers, prevention is of the utmost importance and should focus on moderation of alcohol consumption, vaccination/treatment of hepatitis viral infections and avoidance of overweight and other risk factors of type 2 diabetes.
Center for Primary Health Care Research Lund University 205 02 Malmö Sweden
Comprehensive Cancer Center Helsinki University Hospital 00290 Helsinki Finland
Division of Pediatric Neurooncology German Cancer Research Center D 69120 Heidelberg Germany
See more in PubMed
Valle J.W., Kelley R.K., Nervi B., Oh D.Y., Zhu A.X. Biliary tract cancer. Lancet. 2021;397:428–444. doi: 10.1016/S0140-6736(21)00153-7. PubMed DOI
Villanueva A., Longo D.L. Hepatocellular Carcinoma. N. Engl. J. Med. 2019;380:1450–1462. doi: 10.1056/NEJMra1713263. PubMed DOI
Baumeister S.E., Leitzmann M.F., Linseisen J., Schlesinger S. Physical Activity and the Risk of Liver Cancer: A Systematic Review and Meta-Analysis of Prospective Studies and a Bias Analysis. J. Natl. Cancer Inst. 2019;111:1142–1151. doi: 10.1093/jnci/djz111. PubMed DOI PMC
Hemminki K., Li X. Familial liver and gall bladder cancer: A nationwide epidemiological study from Sweden. Gut. 2003;52:592–596. doi: 10.1136/gut.52.4.592. PubMed DOI PMC
Liu X., Hemminki K., Försti A., Sundquist K., Sundquist J., Ji J. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int. J. Cancer. 2015;137:903–910. doi: 10.1002/ijc.29440. PubMed DOI
Castro F.A., Liu X., Försti A., Ji J., Sundquist J., Sundquist K., Koshiol J., Hemminki K. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clin. Gastroenterol. Hepatol. 2014;12:1038–1045.e1037. doi: 10.1016/j.cgh.2013.11.007. PubMed DOI
McGee E.E., Castro F.A., Engels E.A., Freedman N.D., Pfeiffer R.M., Nogueira L., Stolzenberg-Solomon R., McGlynn K.A., Hemminki K., Koshiol J. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. Int. J. Cancer. 2019;144:707–717. doi: 10.1002/ijc.31835. PubMed DOI PMC
Sundquist K., Sundquist J., Ji J. Risk of hepatocellular carcinoma and cancers at other sites among patients diagnosed with chronic hepatitis B virus infection in Sweden. J. Med. Virol. 2014;86:18–22. doi: 10.1002/jmv.23754. PubMed DOI
Liu X., Chen Y., Wang Y., Dong X., Wang J., Tang J., Sundquist K., Sundquist J., Ji J. Cancer risk in patients with hepatitis C virus infection: A population-based study in Sweden. Cancer Med. 2017;6:1135–1140. doi: 10.1002/cam4.988. PubMed DOI PMC
IARC Ionizing radiation, part 2: Some internally deposited radionuclides. Views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 14–21 June 2000. IARC Monogr. Eval. Carcinog. Risks Hum. 2001;78:1–559. PubMed PMC
Henriksson M., Björnsson B., Eilard M.S., Lindell G., Strömberg C., Hemmingsson O., Isaksson B., Rizell M., Sandström P. Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv. BJS Open. 2020;4:109–117. doi: 10.1002/bjs5.50226. PubMed DOI PMC
Arnold M., Pandeya N., Byrnes G., Renehan P.A.G., Stevens G.A., Ezzati P.M., Ferlay J., Miranda J.J., Romieu I., Dikshit R., et al. Global burden of cancer attributable to high body-mass index in 2012: A population-based study. Lancet Oncol. 2015;16:36–46. doi: 10.1016/S1470-2045(14)71123-4. PubMed DOI PMC
IARC Radiation. Volume 100 D. A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 2012;100:1–341. PubMed
McGee E.E., Jackson S.S., Petrick J.L., Van Dyke A.L., Adami H.O., Albanes D., Andreotti G., Beane-Freeman L.E., de Gonzalez A.B., Buring J.E., et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. J. Natl. Cancer Inst. 2019;111:1263–1278. doi: 10.1093/jnci/djz103. PubMed DOI PMC
Frank C., Fallah M., Ji J., Sundquist J., Hemminki K. The population impact of familial cancer, a major cause of cancer. Int. J. Cancer. 2014;134:1899–1906. doi: 10.1002/ijc.28510. PubMed DOI
Hemminki K., Hemminki O., Forsti A., Sundquist K., Sundquist J., Li X. Familial risks for gallstones in the population of Sweden. BMJ Open Gastroenterol. 2018;4:e000188. doi: 10.1136/bmjgast-2017-000188. PubMed DOI PMC
Turati F., Edefonti V., Talamini R., Ferraroni M., Malvezzi M., Bravi F., Franceschi S., Montella M., Polesel J., Zucchetto A., et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology. 2012;55:1416–1425. doi: 10.1002/hep.24794. PubMed DOI
Yang Y., Wu Q.J., Xie L., Chow W.H., Rothman N., Li H.L., Gao Y.T., Zheng W., Shu X.O., Xiang Y.B. Prospective cohort studies of association between family history of liver cancer and risk of liver cancer. Int. J. Cancer. 2014;135:1605–1614. doi: 10.1002/ijc.28792. PubMed DOI PMC
Kamsa-ard S., Kamsa-ard S., Luvira V., Suwanrungruang K., Vatanasapt P., Wiangnon S. Risk Factors for Cholangiocarcinoma in Thailand: A Systematic Review and Meta-Analysis. Asian Pac. J. Cancer Prev. 2018;19:605–614. doi: 10.22034/apjcp.2018.19.3.605. PubMed DOI PMC
Rawla P., Sunkara T., Thandra K.C., Barsouk A. Epidemiology of gallbladder cancer. Clin. Exp. Hepatol. 2019;5:93–102. doi: 10.5114/ceh.2019.85166. PubMed DOI PMC
Hemminki K., Hemminki A., Försti A., Sundquist K., Li X. Genetics of gallbladder cancer. Lancet Oncol. 2017;18:e296. doi: 10.1016/S1470-2045(17)30324-8. PubMed DOI
Li X., Xu W., Kang W., Wong S.H., Wang M., Zhou Y., Fang X., Zhang X., Yang H., Wong C.H., et al. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics. 2018;8:1740–1751. doi: 10.7150/thno.22010. PubMed DOI PMC
Mehrotra R., Tulsyan S., Hussain S., Mittal B., Saluja S.S., Singh S., Tanwar P., Khan A., Javle M., Hassan M.M., et al. Genetic landscape of gallbladder cancer: Global overview. Mutat. Res. Rev. Mutat. Res. 2018;778:61–71. doi: 10.1016/j.mrrev.2018.08.003. PubMed DOI
Dominguez-Valentin M., Sampson J.R., Seppälä T.T., Ten Broeke S.W., Plazzer J.P., Nakken S., Engel C., Aretz S., Jenkins M.A., Sunde L., et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: Findings from the Prospective Lynch Syndrome Database. Genet. Med. Off. J. Am. Coll. Med. Genet. 2020;22:15–25. doi: 10.1038/s41436-019-0596-9. PubMed DOI PMC
Møller P., Seppälä T.T., Bernstein I., Holinski-Feder E., Sala P., Evans D.G., Lindblom A., Macrae F., Blanco I., Sijmons R.H., et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: A report from the Prospective Lynch Syndrome Database. Gut. 2018;67:1306–1316. doi: 10.1136/gutjnl-2017-314057. PubMed DOI PMC
Li X., Wu Y., Suo P., Liu G., Li L., Zhang X., Chen S., Xu M., Song L. Identification of a novel germline frameshift mutation p.D300fs of PMS1 in a patient with hepatocellular carcinoma: A case report and literature review. Medicine. 2020;99:e19076. doi: 10.1097/MD.0000000000019076. PubMed DOI PMC
Golan T., Raitses-Gurevich M., Kelley R.K., Bocobo A.G., Borgida A., Shroff R.T., Holter S., Gallinger S., Ahn D.H., Aderka D., et al. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017;22:804–810. doi: 10.1634/theoncologist.2016-0415. PubMed DOI PMC
Hemminki K., Ji J., Brandt A., Mousavi S.M., Sundquist J. The Swedish Family-Cancer Database 2009: Prospects for histology-specific and immigrant studies. Int. J. Cancer. 2010;126:2259–2267. doi: 10.1002/ijc.24795. PubMed DOI
Ludvigsson J.F., Andersson E., Ekbom A., Feychting M., Kim J.L., Reuterwall C., Heurgren M., Olausson P.O. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi: 10.1186/1471-2458-11-450. PubMed DOI PMC
Li X., Hemminki K. Cancer risks in women who had children with different partners from the Swedish Family-Cancer Database. Eur. J. Cancer Prev. 2002;11:433–438. doi: 10.1097/00008469-200210000-00005. PubMed DOI
Li X., Hemminki K. Cancer risks in men who had children with different partners from the Swedish Family-Cancer Database. Eur. J. Cancer Prev. 2003;12:355–358. doi: 10.1097/00008469-200310000-00002. PubMed DOI
Zheng G., Sundquist K., Sundquist J., Chen T., Försti A., Hemminki A., Liska V., Hemminki K. Second Primary Cancers after Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers. Clin. Epidemiol. 2021;13:683–691. doi: 10.2147/CLEP.S318737. PubMed DOI PMC
Hemminki K., Tretli S., Sundquist J., Johannesen T.B., Granstrom C. Familial risks in nervous-system tumours: A histology-specific analysis from Sweden and Norway. Lancet Oncol. 2009;10:481–488. doi: 10.1016/S1470-2045(09)70076-2. PubMed DOI
Xue Y., Balci S., Mericoz C.A., Taskin O.C., Jiang H., Pehlivanoglu B., Muraki T., Memis B., Saka B., Kim G.E., et al. Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. Cancer. 2020;126:4788–4799. doi: 10.1002/cncr.33135. PubMed DOI
Wong W., Lowery M.A., Berger M.F., Kemel Y., Taylor B., Zehir A., Srinivasan P., Bandlamudi C., Chou J., Capanu M., et al. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer. 2019;125:1441–1448. doi: 10.1002/cncr.31951. PubMed DOI PMC
Hemminki K., Sundquist K., Sundquist J., Försti A., Hemminki A., Li X. Familial Risks and Proportions Describing Population Landscape of Familial Cancer. Cancers. 2021;13:4385. doi: 10.3390/cancers13174385. PubMed DOI PMC
